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Abstract
Modulation of the immune system by genetically modified immunological effector cells is of
potential therapeutic value in the treatment of malignancies. Interleukin-2 (IL-2) is a crucial cytokine
which induces potent antitumor response. Cytokine-induced killer cells (CIK) have been described
as highly efficient cytotoxic effector cells capable of lysing tumor cell targets and are capable of
recognizing these cells in a non-MHC restricted fashion. Dendritic cells (DC) are the major antigen
presenting cells. This study evaluated the antitumor effect of CIK cells which were non-virally
transfected with IL-2 and co-cultured with pulsed and unpulsed DC. Human CIK cells generated
from peripheral blood were transfected in vitro with plasmid encoding for the human IL-2.
Transfection involved a combination of electrical parameters and a specific solution to deliver
plasmid directly to the cell nucleus by using the Nucleofector®  electroporation system.
Nucleofection resulted in the production of IL-2 with a mean of 478.5 pg/106 cells (range of 107.6–
1079.3 pg /106 cells/24 h) compared to mock transfected CIK cells (31 pg/106 cells) (P = 0.05). After
co-culturing with DC their functional ability was assessed in vitro by a cytotoxicity assay. On
comparison with non-transfected CIK cells co-cultured with DCs (36.5 ± 5.3 %), transfected CIK
cells co-cultured with DC had a significantly higher lytic activity of 58.5 ± 3.2% (P = 0.03) against
Dan G cells, a human pancreatic carcinoma cell line.
Introduction
Advances in the characterization of cytokines and tumor
antigens, coupled with our increasing ability to manipu-
late gene expression, have fostered a new era of tumor
immunotherapy [1]. Interleukin-2 (IL-2) affects a variety
of components of the cellular immune system, including
B cells and macrophages by inducing the secretion of
tumor necrosis factors (TNF) α and β and interferon-γ.
Mainly, IL-2 is responsible for the proliferation of T cells.
In animal and some human studies, systemic administra-
tion of IL-2 has antitumor effects, mediated by cytotoxic
effector cells (such as lymphokine-activated killer – LAK
cells and cytotoxic T lymphocytes) [2]. Such systemic
administration often induces high toxicity and is shown
to be inferior to local continuous production of cytokine,
for recruitment of T cells [3]. Cytokine-induced killer cells
(CIK) are non-major histocompatibility complex-
restricted cytotoxic lymphocytes generated by incubation
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of peripheral blood lymphocytes with anti-CD3 mono-
clonal antibody, interleukin (IL)-2, IL-1 and interferon
gamma (IFN-γ). CIK represent cells with high antitumor
cytotoxicity in vitro and in vivo [4]. CIK cells possess
enhanced cytotoxic activity as compared to standard lym-
phokine activated killer (LAK) cells [5,6]. CIK cells,
express CD4 (45.4+/-3.2) % and CD8(47.7+/-11.0%)
markers. It has been shown that NKT cells co-expressing
CD3 and CD56 markers on their surface represent the
major cytotoxic subset of CIK cells [7]. These NKT cells are
derived from T cells [5]. Because of the increase in cytotox-
icity and high proliferative response, CIK cells have a 73-
fold increase in total lytic units per culture as compared to
IL-2-stimulated LAK cells. Gene transfers of cytokine
genes to CIK and tumor cells have been extensively stud-
ied. CIK cells transfected with cytokine genes have shown
to induce antitumor effects [8].
Dendritic cells (DC) are specialized antigen-presenting
cells located throughout the human body. They represent
heterogeneous cell population, residing in most periph-
eral tissues where they represent 1–2% of the cell num-
bers. In the absence of ongoing inflammatory and
immune responses, dendritic cells constitutively patrol
through the blood, peripheral tissues, lymph and second-
ary lymphoid organs [9]. Morphologically, mature DC are
large cells with elongated and stellated processes. They
express high levels of MHC I and II, CD11 a, b, c, CD40,
CD54, CD58, CD80, CD83, CD86. The most typical
markers at present are MHC I, II and co-stimulatory mark-
ers such as CD80, CD86, [10] which present signals to
CD4 and CD8 positive T cells. Once T cells are activated
after interaction with a DC exhibiting the appropriate
tumor-associated peptide antigen and class I molecule,
they kill other cells that express these molecules such as
tumor cells.
Exocrine pancreatic carcinomas have a very poor progno-
sis and a resistance to conventional therapy. This is mainly
induced by lack of immuno-competent cells. Therefore, it
might be beneficial for patients with pancreatic cancer to
induce an immune attack against the tumor by inserting a
cytokine gene into the immunological effector cells. The
aim of this study was to evaluate the antitumor immune
responses of a cytokine immunotherapy using gene trans-
fer to provide continuous and local cytokine production
and therefore showing an improved cytotoxic effect
against pancreatic cancer cells.
Material and methods
Generation of dendritic cells
DC were generated as described before [4,7]. Blood was
drawn according to our protocol accepted by the local eth-
ics committee from healthy volunteers. Briefly, peripheral
blood lymphocytes were isolated from buffy coats by
Ficoll density gradient centrifugation (Lymphoprep,
Nycomed, Oslo Norway). These cells were allowed to
adhere in six-well-plates at a density of 5 × 106 cells/ml for
one hour at 37°C in complete RPMI 1640 with 10% heat-
inactivated fetal calf serum, 100 U/ml penicillin and 100
µg/ml streptomycin. The non-adherent cells were col-
lected for generating CIK cells. The adherent cells were cul-
tured in 2 ml RPMI 1640 with autologous, heat-
inactivated serum, 750 IU GM-CSF and 500 IU IL-4 (Essex
Pharma, Nürnberg, Germany), 100 U/ml penicillin and
100 µg/ml streptomycin per well for seven days for gener-
ating DC. The media along with the necessary cytokines
were changed every third day.
Generation of CIK
CIK cells were generated as described previously [11]. In
brief, non-adherent Ficoll separated human peripheral
blood mononuclear cells derived from healthy individu-
als were prepared and grown in RPMI 1640 medium
(Gibco BRL, Berlin, Germany), containing 10% fetal calf
serum (Gibco BRL), 25 mM Hepes, 100 U/ml penicillin
and 100 µg/ml streptomycin. One thousand IU/ml
human recombinant interferon γ (Boehringer Mannheim,
Germany) was added on day 0. After 24 hrs of incubation,
50 ng/ml of an anti-CD3 (Orthoclone OKT 3, Cilag
GmbH, Sulzbach, Germany), 100 U/ml interleukin-1β
and 300 U/ml interleukin-2 (R and D Systems, Wies-
baden, Germany) were added. Cells were incubated at
37°C in a humidified atmosphere of 5% CO2 and sub-cul-
tured every third day in fresh complete medium with 300
U/ml IL-2 at 3 × 106 cells/ml. CIK cells were harvested on
day +7 and were co-cultured for seven days with autolo-
gous DC at a stimulator (DC) to responder (CIK) ratio of
1:5.
Cell lines
The human pancreatic carcinoma cell line DAN-G was
purchased from DSMZ (Deutsche Sammlung für Zellkul-
tur, Braunschweig, Germany). The cells were maintained
in RPMI 1640 supplemented with 10% fetal calf serum
(FCS, PAA) 100 U/ml penicillin and 100 µg/ml strepto-
mycin (Seromed, Jülich, Germany) and grown at 37°C in
a humidified atmosphere of 5% CO2.
Preparation of IL-2 plasmid
cDNA of human IL-2 was cloned in the plasmid pMTV.05
(Invitrogen, Karlsruhe, Germany). The recombinant
pMTv-hIL-2 (referred to as pIL-2) was transformed and
the plasmid was eluted using a mini-prep column (Qia-
gen GmbH, Hilden Germany) according to the manufac-
turer's protocol.
Pulsing of DC
DCs were pulsed with tumor lysate of Dan-G cells on day
+5 [12].Genetic Vaccines and Therapy 2004, 2:12 http://www.gvt-journal.com/content/2/1/12
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Gene transfer by nucleofection
CIK cells were subjected to a combination of electrical
parameters and specific solution to deliver the DNA
directly to the cell nucleus under mild conditions by using
a commercially available nucleofection system on day 10
according to manufacturer's protocol (Nucleofector
Amaxa Biosystems GmbH, Cologne, Germany). Five
times 106 CIK cells were nucleofected in an electropora-
tion cuvette along with pre-warmed nucleofector solution
and 3 µg of pMTV-hIL-2 using the programme U-14. Once
nucleofected, CIK cells were transferred into fresh pre-
warmed media with the necessary cytokines and serum.
IL-2 measurement
Cell culture supernatants from the nucleofected and non-
nucleofected CIK cells were sampled at 24 hrs and 48 hrs,
respectively. An enzyme linked immunosorbent assay for
IL-2 with matched antibody pairs was performed accord-
ing to the manufacturer's instructions (R and D Systems,
Wiesbaden, Germany).
Cytotoxicity assay
A DELFIA EuTDA® non-radioactive cytotoxicity assay was
used as a fluorometric alternative to the 51Cr release assay
(Perkin Elmer Wallac Life Sciences, Brussels, Belgium).
The assay is based on loading target cells with a fluores-
cence enhancing ligand. After cytolysis the ligand is
released and introduced to the DELFIA® Europium solu-
tion. The measured signal correlates directly with the
amount of lysed cells [13]. Each experiment was per-
formed in triplicates and the mean value was calculated.
After incubation, 20-microl aliquots from all wells are
transferred to a fresh 96-well plate. To each well of the
plate, 180 microl of the Europium solution mix is added
and incubated at room temperature for 15 min on a
shaker. Fluorescence data are collected using a 96-well
plate in a time-resolved fluorometer (PerkinElmer, Brus-
sels, Belgium). Maximum release was obtained by incu-
bating Dan-G cells with 1% lysis Buffer (Perkin Elmer
Wallac Life Sciences, Brussels, Belgium). Target cells with-
out effector cells are used as negative control (spontane-
ous release). Specific releases are calculated as percentage
cytotoxicity = experimental release (counts) minus spon-
taneous release (counts) divided through maximum
release (counts) minus spontaneous release (counts) of
target cells.
Students't' test was applied. A P value < 0.05 was consid-
ered significant.
Results
In vitro generation of DC and CIK
DC were generated from CD14+ monocytes using GM-CSF
and IL-4. Adherent cells showed cytoplasmic processes
typical for DC. After co-culture with CIK cells they formed
typical cluster. Flow cytometry showed CD14 negative
populations, expressing markers typical for DC (CD80+,
CD83+, CD86+ and HLA-DR expressing cells). The CIK
cells were phenotyped with antibodies against CD3, CD8,
CD16, CD40L, CD56, HLA-ABC and HLA-DR. Data was
similar to other studies by our group (data not shown)
[5,11,14].
Transfection efficiency
Transfection efficiency was determined by eGFP expres-
sion analysis using a fluorescence activated cell sorter. Via-
ble cells were determined by propidium iodide staining.
Nucleofection efficiency for eGFP gene transfer into the
stimulated CIK cells resulted in a transient expression of
43 +/- 3.8% of the cells after 24 hours. 17% of the cells
were not viable after transfection. The amount of IL-2 was
the maximum after 24 hrs. An irrelevant plasmid contain-
ing eGFP was nucleofected and compared to the plasmid
containing the IL-2 insert in various samples (n = 8).
Nucleofection resulted in the production of IL-2 with a
mean of 478.5 pg /106 cells (range of 107.6–1079.3 pg /
106 cells/24 h) compared to irrelevantly transfected (con-
taining eGFP) CIK cells (31 pg/106 cells) (P = 0.05). CIK
cells secreting IL-2 were co-cultured from days +7 to +14
with DC, 10 days of age. Cytotoxicity of effector cells was
analyzed. Co-culture of effector cells with DC led to an
increase in cytotoxic activity as measured in a Eu-release
assay using Dan-G. Eu-release in co-cultured CIK cells
transfected with pIL-2 and DC was 58.5 ± 3.2% at an effec-
tor:target ratio of 1:40 (Fig. 1) compared to non-trans-
fected CIK cells co-cultured with DC (36.5 ± 5.3%, P =
0.03). In order to further enhance cytotoxic activity DC
were pulsed with tumor lysate of Dan-G cells on day +5.
However, lytic activity (50.3%) was not significantly
enhanced (P = 0.33) when compared to non-transfected
cells (Fig. 1). Lytic activity of DCs pulsed with tumor
lysate and co-cultured with non-transfected CIK cells was
48.9% where as DC pulsed with tumor lysate and co-cul-
tured with CIK cells transfected without the plasmid was
46.3% and CIK cells alone 40.3% (Fig. 1).
Discussion
In this report, transfection of CIK cells with IL-2 demon-
strated a prominent augmentation of antitumor immu-
nity  in vitro against pancreatic carcinoma cell lines via
secreting significant amounts of IL-2.
Ductal pancreatic adenocarcinoma is the fourth leading
cause of cancer death in the Western world. Unfortu-
nately, recent advances in diagnostics, staging, and ther-
apy have not resulted in significant improvements. Thus,
new approaches are necessary to improve the outcome of
patients with exocrine pancreatic cancer. CIK cells are the
most potent mediators of the lyses of autologous and all-
ogeneic cancer cells in vitro in a non MHC restrictedGenetic Vaccines and Therapy 2004, 2:12 http://www.gvt-journal.com/content/2/1/12
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fashion [15], have a higher antitumor toxicity as com-
pared to standard lymphokine activated cells [5,6,15] and
may be suitable to remove tumor cells resistant to chemo-
therapy [8]. Therefore, they are ideal candidates for fur-
ther enhancing cytotoxic activity. CIK cells have been
shown to upregulate DC specific markers [16]. Transgene
candidates to potentially activate systemic immune
response include genes encoding for co-stimulatory mol-
ecules, lymphotactic chemokines, allogeneic MHC mole-
cules, or cytokines like IL-2. Because of the serious toxicity
of systemically administered IL-2 observed in clinical
practice [17] it can be expected that local expression of IL-
2 is less harmful to the patient than systemic administra-
tion to trigger the immune system. In this regard, adeno-
viral-mediated expression of IL-2 cytokine gene in several
tumor models has been found to induce strong and spe-
cific antitumor responses [18] by stimulating immune
cells including T and natural killer cells. But adenoviral
transfection may raise safety questions in human gene
therapy. Therefore, we were interested in evaluating the
Cytotoxic activity of immunological effector cells that had been co-cultured with DC against Dan-G pancreatic carcinoma cells Figure 1
Cytotoxic activity of immunological effector cells that had been co-cultured with DC against Dan-G pancreatic carcinoma cells. 
Immunological effector cells from a donor were co-cultured from days +10 to +14 with autologous DC cultures seven days of 
age, as described in materials and methods. DC were pulsed at day +7 with 200 ng/ml of tumor lysate. Cytotoxic activity at 
various effector to target cell ratios was measured by Europium release assay. Dan-G cells were used as targets. Data repre-
sent results of three separate experiments and are shown as mean. CIKs = CIKS cells only DC+CIKS = naive DC co-cultured 
with CIK cells DC+CIKSpIL-2 = naive DC co-cultured with CIK cells nucleofected with pIL-2 DC-Tu+CIKS = DC pulsed with 
tumor lysate and co-cultured with CIK cells DC-Tu+CIKSpIL-2 = DC pulsed with tumor lysate and co-cultured with CIK cells 
nucleofected with pIL-2 DC-Tu+CIKS (nucleofected) = DC pulsed with tumor lysate and co-cultured with CIK cells nucleo-
fected without plasmidGenetic Vaccines and Therapy 2004, 2:12 http://www.gvt-journal.com/content/2/1/12
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potential of IL-2 non-viral transfected CIK cells for their
ability to stimulate and activate immunologic effector
cells.
The use of gene transfected lymphocytes were hampered
by a poor efficiency of gene transfer in lymphocytes and a
down regulation of cytokine expression [19]. In contrast,
nucleofection is a fast and cost-effective method for trans-
fection of large amounts of cells. Here, nucleofection
resulted in a significant higher production of IL-2 com-
pared to mock transfected CIK cells (P = 0.05). This results
matches perfect to a previously reported result by our
group [8]. To the best of our knowledge no further report
about nucleofection of CIK cells were available. We then
showed, that transfection of CIK cells with IL-2 enhances
cytotoxic activity (Fig. 1) compared to non-transfected
CIK cells co-cultured with DC. No significant cytotoxic
activity was seen when DC were pulsed with tumor lysate
of Dan-G cells were used with IL-2 transfected CIK cells.
This may be due to inhibitory factors in the tumor lysate
which may contribute to a decrease in lytic activity.
This effect is due to increased amounts of CIK cells during
co-cultivation of IL-2 secreting CIK cells with DC. IL-2
secretion by the CIK cells enhances the NK cell antitumor
activity [20]. NK cells proliferate in the presence of IL-2
[21]. This led to a higher amount of effector cells resulting
in a higher cytotoxic activity. This effect of inducing pro-
liferation of tumoricidal lymphocytes is well known and
the most important biologic effect of IL-2 on immune
cells. The reproducible observation that virtually all
malignant cells can be lysed by IL-2 stimulated lym-
phocytes in a manner directly related to the intensity of IL-
2 administration encouraged the pursuit of aggressive,
intensive clinical trials, especially in renal cell carcinoma
and melanoma. Several authors have shown the efficacy
of transfecting primary tumor cells and tumor cell lines
with plasmid DNA/lipid complexes [22]. Local produc-
tion of high concentrations of IL-2 and IFN-alpha at the
tumor site was more effective in preventing tumor growth
than systemic administration in patients with metastatic
renal cell carcinoma [22]. There are several reports intro-
ducing IL-2 producing genes into pancreatic cancer, but
there are no reports about IL-2 secreting lymphocytes
functioning as immune enhancer cells. Therefore, our
report is the first describing CIK cells to have enhanced in
vitro cytolytic activity via non-viral interleukin-2 gene
transfer against pancreatic cancer cell lines. Direct delivery
of plasmid IL-2 gene to the established tumors in mice
showed an increase in both early and long term survival
[3]. Preclinical efficacy studies in a renal cell carcinoma,
murine model also showed that direct intra-tumoral
administration of an IL-2 plasmid DNA/DMRIE/DOPE
complex resulted in the generation of tumor specific lym-
phocytes and complete tumor regression [23]. It is reason-
able too, that these effector cells given in a pancreatic
carcinoma model should enhance cytotoxic activity.
These investigations are ongoing.
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